Diagnostic test: adalimumab trough concentration    (DrugBank: Adalimumab)

1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis1

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04251741
(ClinicalTrials.gov)
March 1, 20208/1/2020Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab TreatmentUsing Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment: a Blinded Randomized Superiority TrialRheumatoid ArthritisDiagnostic Test: Adalimumab trough concentration;Other: Usual careReade Rheumatology Research InstituteZonMw: The Netherlands Organisation for Health Research and Development;Sint MaartenskliniekRecruiting18 YearsN/AAll84Phase 4Netherlands